Non Small Cell Lung Cancer Clinical Trial
— NVALT12Official title:
A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12
NCT number | NCT01171170 |
Other study ID # | NVALT12 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | January 2011 |
Est. completion date | August 2020 |
Verified date | September 2020 |
Source | Dutch Society of Physicians for Pulmonology and Tuberculosis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to assess the effects of adding nitroglycerin (NTG) patches, delivery
25 mg NTG per 24 h, to the standard first line treatment of metastatic non-squamous non-small
cell lung cancer (NSCLC), i.e. 4 cycles of carboplatin-paclitaxel-bevacizumab, followed by
bevacizumab alone until disease progression. Tumor hypoxia is a common phenomenon in lung
cancer; it is a known poor prognostic marker, related to treatment resistance. Pre-clinical
studies have shown that nitric oxide (NO) donating drugs may decrease hypoxia related drug
resistance. NTG is a NO donating drug. NTG increases tumor blood flow and thereby augments
antitumor drug delivery to the tumor.
A randomized phase II has shown an increase in the response rate from 42% to 72%, when NTG
patches (25 mg/day, day -2 to +3) were added to vinorelbine/cisplatin in patients with
advanced NSCLC. In addition, the time to progression increased from 185 to 327 days.
The hypothesis of the present study is that adding NTG transdermal patches to bevacizumab
containing chemotherapy improves progression free survival, response rate and overall
survival in patients with metastatic non-squamous NSCLC.
Status | Completed |
Enrollment | 223 |
Est. completion date | August 2020 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically/cytologically proven stage IV non-squamous NSCLC (according to IASLC staging 7.0) - No prior chemotherapy or therapy with systemic anti-tumor therapy (e.g., monoclonal antibody therapy) or prior exposure to agents directed at the HER axis (e.g. epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI), Herceptin). Prior surgery and/or localized palliative irradiation is permitted provided that the irradiated lesion is not the only measurable lesion. Prior adjuvant chemotherapy > 1 year ago and prior treatment with an EGFR-TKI for patients with an activating EGFR mutation is allowed. - Age = 18 years. - ECOG Performance Status of 0 - 2. - Life expectancy of at least 12 weeks. - Subjects with at least one uni-dimensional(for RECIST) measurable lesion. - Adequate bone marrow, liver and renal function. - Adequate non-hormonal contraception for females of childbearing potential during the study and in the 6 months thereafter. - Adequate contraception for male participants (or their partners) during the study and in the 6 months thereafter. Exclusion Criteria: - Clinically significant (i.e. active) cardiovascular disease: congestive heart failure >NYHA class 2; CVA or myocardial infarction < 6 months prior to study entry; uncontrolled hypertension (blood pressure systolic > 150 mmHg and/or diastolic > 100 mmHg). - Symptomatic hypotension. - History of hemoptysis at least grade 2 (bright red blood of at least 2,5 ml in the last 3 months) - Evidence of tumor invading major blood vessels on imaging (i.e. superior vena cava or pulmonary artery). - History of HIV infection or chronic hepatitis B or C. - Active clinically serious infection - Symptomatic metastatic brain or meningeal tumors. Patients with brain metastasis may be included the patient is treated with brain radiotherapy and asymptomatic. - History of organ allograft. - Patients with evidence or history of bleeding diathesis. - Non-healing wound or ulcer. - History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment - Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study entry - Radiotherapy within 4 weeks of start of study drug. Palliative radiotherapy for bone lesions is allowed > 14 days of start of chemotherapy. Major surgery within 4 weeks of start of study. - Use of vasodilators (including 5-phosphodiesterase inhibitors, calcium antagonists or nitrates) - Autologous bone marrow transplant or stem cell rescue within 4 months of study - Investigational drug therapy outside of this trial during or within 4 weeks of study entry - Pregnancy or lactation. |
Country | Name | City | State |
---|---|---|---|
Netherlands | VU medisch centrum | Amsterdam | |
Netherlands | Amphia Ziekenhuis | Breda | |
Netherlands | Jeroen Bosch Ziekenhuis | Den Bosch | |
Netherlands | Catharina-Ziekenhuis | Eindhoven | |
Netherlands | Martini Ziekenhuis | Groningen | |
Netherlands | Maastricht UMC | Maastricht | |
Netherlands | HagaZiekenhuis | The Hague | |
Netherlands | Isala Klinieken | Zwolle |
Lead Sponsor | Collaborator |
---|---|
Dutch Society of Physicians for Pulmonology and Tuberculosis |
Netherlands,
de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, Dingemans AC, Kunert A, Hendriks RW, Aerts JGJV. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Ce — View Citation
de Jong EE, van Elmpt W, Leijenaar RT, Hoekstra OS, Groen HJ, Smit EF, Boellaard R, van der Noort V, Troost EG, Lambin P, Dingemans AC. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-be — View Citation
Degens JHRJ, Sanders KJC, de Jong EEC, Groen HJM, Smit EF, Aerts JG, Schols AMWJ, Dingemans AC. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer. Lung Cancer. 20 — View Citation
Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitrog — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression free survival | Imaging | every 6 weeks during chemotherapy | |
Secondary | objective response rate | Imaging | every 6 weeks during chemotherapy | |
Secondary | disease control rate | Imaging | every 6 weeks during chemotherapy | |
Secondary | duration of response | Imaging | every 6 weeks during chemotherapy | |
Secondary | safety of the treatment | adverse events, hematology, chemistry, physial examination | every 3 weeks during chemotherapy | |
Secondary | prediction of early response | FDG PET scan (exploratory objective) | after 3 weeks | |
Secondary | decreased hypoxia | FAZA scan (exploratory objective) | after 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 |